Dickinson Andrew D sold $376K of GILD
Dickinson Andrew D (Chief Financial Officer) sold 3,000 shares of GILEAD SCIENCES, INC. (GILD) at $125.40 ($0.38M total) on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider activity but does not include any new operational, financial, or regulatory information that would directly reprice the business.
Market read
Traders may monitor for follow-on insider activity, but the 10b5-1 framing makes this more of a sentiment datapoint than a catalyst.
What to watch
The article provides only the sale size and plan type; it does not indicate whether other insiders bought, whether there were concurrent corporate events, or whether the sale was tax/compensation-driven.
Background
This is an SEC Form 4 insider transaction disclosure for Gilead Sciences, filed via EDGAR.
Ticker impact
Gilead CFO Andrew D. Dickinson sold 3,000 shares in an open-market transaction under a pre-arranged 10b5-1 plan on 2026-06-15.
Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other news.
The filing is a Form 4 insider sale with a stated 10b5-1 plan, which typically reduces interpretability versus discretionary selling.
Market effects
Minimal—single-company insider transaction without guidance, trial, or regulatory updates.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s private view of near-term risk; traders may treat it as a mild bearish sentiment input.
Key entities
- issuerGilead Sciences, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderAndrew D. Dickinson
CFO who sold 3,000 shares under a pre-arranged 10b5-1 plan.
